Bob More

Bob More has held partner-level roles at leading life-science venture capital firms Frazier Healthcare Partners, Domain Associates, and is currently a partner at Alta Partners. He has managed successful investments by serving on the boards of Sienna Biopharmaceuticals, ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), NovaCardia (acquired by Merck), Esprit Pharma (acquired by Allergan), IntraLase (acquired by Advanced Medical Optics, Inc.), Oceana Therapeutics (acquired by Salix Pharmaceuticals), Achaogen (NASDAQ: AKAO), Neothetics, (NASDAQ: NEOT), Glaukos Corporation (NYSE: GLKS), and a founding board member of the Kauffman Fellows Program. In addition, Bob was an investor in Clovis Pharmaceuticals, Affinivax, and Sienna Labs. Currently, he is a Senior Advisor of Venture Investing at the Bill & Melinda Gates Foundation and serves on the boards of One Revolution and The Foundation for Innovative New Diagnostics (FIND). He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.